Kiora Pharmaceuticals (FRA:7EY) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7EY Kiora Pharmaceuticals Inc FRA:7EY
34 GF Score
Price €0.42
! 4 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:7EY
34GF Score
Kiora Pharmaceuticals Inc FRA:7EY
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals Business Description

Other Exchanges KPRX:USA
Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company based in the United States that develops therapies for orphan retinal diseases and inflammatory eye conditions. Its lead candidate, KIO-301, is a molecular photoswitch designed to restore vision in patients with inherited or age-related retinal degeneration, including retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a next-generation, non-steroidal, immunomodulatory small-molecule inhibitor of dihydroorotate dehydrogenase, for posterior non-infectious uveitis. Kiora targets specialty ophthalmic markets, focusing on conditions with limited treatment options and orphan drug designations. As a clinical-stage company, it does not yet generate product revenue; its operations are funded primarily through equity financings, partnerships, and research collaborations, with value expected to be driven by clinical trial progress and regulatory milestones.
34GF Score

Get the complete analysis for FRA:7EY

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price